Dr Fiona Pathiraja, Md, Mba, Mph

Pear Bio analyzes patient tumor samples and data with a proprietary computational biology platform to deconvolute complex cancer biology and drive patient-centric functional precision medicine and drug discovery. Our ultimate goal is to optimally allocate approved treatments to cancer patients who will benefit from them, while creating novel therapies that are purpose-designed for patients who dont respond to available treatments. The platform uses microphysiological systems and 3D computer vision to measure cancer progression over time. Pear Bio cultures patient tumor samples with matched blood into 3D immune-microtumors to test potential treatment options and combinations ex vivo. A proprietary computer vision/DL pipeline finds image-based spatial biomarkers in time-course 3D microscopy data of patient 3D immune-microtumors. Each treatment option is compared using these image biomarkers to predict which treatments have high potential efficacy for each patient. Patient data and excess tissue/blood feed into a multi-omics pipeline, which allows us to find novel druggable targets in patients who dont respond to approved therapies. These targets are then developed into our in-house drug discovery pipeline, which eventually feeds back into clinical care through our predictive biomarker platform.

We augment Radiology through AI & machine learning focusing on MSK X-Ray analysis. We are on a mission to ensure every patient receives affordable, accessible, expert level diagnosis by building technology that augments and eventually automates reading of x-ray images. All while lowering the radiologist dependency.

Cerebriu’s proven radiology AI solutions detect findings during the initial scan and enable the most appropriate procedures while the patient is still in the scanner. This leads to a simpler, faster MR image acquisition and creates tangible clinical value: Improving technologists’ confidence and freeing up radiologists’ time by ensuring the right data the first time the patient is in the scanner Timely diagnosis of critical findings by prioritizing radiologists’ worklists Improving patient experience and reducing patient recalls

Arthronica is a digital platform that leverages computer vision to monitor chronic arthritis.

Investing in healthtech startups at the earliest stages.

This is a catchall company for the doers, the thinkers, and the innovators.

Pear Bio analyzes patient tumor samples and data with a proprietary computational biology platform to deconvolute complex cancer biology and drive patient-centric functional precision medicine and drug discovery. Our ultimate goal is to optimally allocate approved treatments to cancer patients who will benefit from them, while creating novel therapies that are purpose-designed for patients who dont respond to available treatments. The platform uses microphysiological systems and 3D computer vision to measure cancer progression over time. Pear Bio cultures patient tumor samples with matched blood into 3D immune-microtumors to test potential treatment options and combinations ex vivo. A proprietary computer vision/DL pipeline finds image-based spatial biomarkers in time-course 3D microscopy data of patient 3D immune-microtumors. Each treatment option is compared using these image biomarkers to predict which treatments have high potential efficacy for each patient. Patient data and excess tissue/blood feed into a multi-omics pipeline, which allows us to find novel druggable targets in patients who dont respond to approved therapies. These targets are then developed into our in-house drug discovery pipeline, which eventually feeds back into clinical care through our predictive biomarker platform.

We augment Radiology through AI & machine learning focusing on MSK X-Ray analysis. We are on a mission to ensure every patient receives affordable, accessible, expert level diagnosis by building technology that augments and eventually automates reading of x-ray images. All while lowering the radiologist dependency.

Cerebriu’s proven radiology AI solutions detect findings during the initial scan and enable the most appropriate procedures while the patient is still in the scanner. This leads to a simpler, faster MR image acquisition and creates tangible clinical value: Improving technologists’ confidence and freeing up radiologists’ time by ensuring the right data the first time the patient is in the scanner Timely diagnosis of critical findings by prioritizing radiologists’ worklists Improving patient experience and reducing patient recalls

Arthronica is a digital platform that leverages computer vision to monitor chronic arthritis.

IPQ Capital is a private investment office based in Copenhagen. Were laser-focused on long-term results and maximum value creation. Offices in DK & UK.